Loading...
Loading...
NGM| Name | Value |
|---|---|
| Revenues | 0.6M |
| Cost of Revenue | 0.5M |
| Gross Profit | 0.1M |
| Operating Expense | 31.6M |
| Operating I/L | -31.0M |
| Other Income/Expense | 2.2M |
| Interest Income | 2.2M |
| Pretax | -28.8M |
| Income Tax Expense | -2.2M |
| Net Income/Loss | -28.8M |
NGM Biopharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of novel therapeutics for liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates, including Aldafermin and MK-3655, are in advanced clinical trials for the treatment of non-alcoholic steatohepatitis (NASH), type 2 diabetes, and other conditions. Additionally, NGM Biopharmaceuticals has a range of other promising products under development, such as NGM120, NGM621, NGM707, NGM831, and NGM438, targeting various diseases. The company generates revenue through research collaborations, product development, and license agreements with pharmaceutical partners, such as Merck Sharp & Dohme Corp. and Merck & Co., Inc.
